Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). This study evaluated addition of daratumumab (D) to RVd in ASCTeligible NDMM patients. Patients (N=207) were randomized...Continue Reading